Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Grows By 86.7%

Entera Bio Ltd. (NASDAQ:ENTX) experienced a significant increase in short interest, rising 86.7% to 96,900 shares as of October 15th. This represents 0.2% of the stock being short sold, with a short-interest ratio of 0.5 days based on an average trading volume of 201,500 shares. Analysts have mixed ratings on the stock, with an average rating of "Moderate Buy" and a price target of $10.00. Entera Bio's stock opened at $2.91, with a market cap of $132.87 million and a P/E ratio of -11.19. Institutional investors hold 14.11% of the stock.

Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) was the recipient of a significant growth in short interest in October. As of October 15th, there was short interest totaling 96,900 shares, a growth of 86.7% from the September 30th total of 51,900 shares. Based on an average trading volume of 201,500 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.2% of the company's stock are short sold. Approximately 0.2% of the company's stock are short sold. Based on an average trading volume of 201,500 shares, the days-to-cover ratio is currently 0.5 days.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ENTX shares. Weiss Ratings restated a "sell (d-)" rating on shares of Entera Bio in a report on Wednesday, October 8th. HC Wainwright upgraded Entera Bio to a "strong-buy" rating in a report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Entera Bio presently has an average rating of "Moderate Buy" and an average price target of $10.00.

View Our Latest Analysis on ENTX

Entera Bio Stock Up 3.2%

Entera Bio stock opened at $2.91 on Friday. The business has a 50-day simple moving average of $2.10 and a two-hundred day simple moving average of $2.03. The company has a market cap of $132.87 million, a P/E ratio of -11.19 and a beta of 1.68. Entera Bio has a 52-week low of $1.50 and a 52-week high of $2.95.

Entera Bio (NASDAQ:ENTX - Get Free Report) last released its quarterly earnings results on Friday, August 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.05. Entera Bio had a negative return on equity of 77.75% and a negative net margin of 4,525.11%. Research analysts anticipate that Entera Bio will post -0.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Entera Bio

A number of large investors have recently made changes to their positions in the company. HighTower Advisors LLC lifted its position in shares of Entera Bio by 53.3% during the 1st quarter. HighTower Advisors LLC now owns 18,140 shares of the company's stock valued at $31,000 after buying an additional 6,310 shares in the last quarter. Bessemer Group Inc. purchased a new position in shares of Entera Bio during the 2nd quarter valued at about $268,000. Finally, Parkman Healthcare Partners LLC lifted its position in shares of Entera Bio by 6.3% during the 1st quarter. Parkman Healthcare Partners LLC now owns 439,632 shares of the company's stock valued at $747,000 after buying an additional 25,900 shares in the last quarter. 14.11% of the stock is currently owned by institutional investors.

About Entera Bio

(Get Free Report)

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.

Should You Invest $1,000 in Entera Bio Right Now?

Before you consider Entera Bio, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entera Bio wasn't on the list.

While Entera Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here